tazemetostat sold brand name tazverik medication used treatment adults adolescents aged years older metastatic cancer cells spread parts body locally advanced cancer grown outside organ started yet spread distant parts body epithelioid sarcoma eligible complete resection surgically removing tissue structure common side effects pain fatigue nausea decreased appetite vomiting people taking tazemetostat increased risk developing secondary malignancies including tcell lymphoblastic lymphoma type blood cancer affects lymphatic system usually found lymph nodes myelodysplastic syndrome disorder resulting poorly formed dysfunctional blood cells acute myeloid leukemia cancer blood bone tazemetostat cancer drug acts potent selective tazemetostat blocks activity methyltransferase may help keep cancer cells cases epithelioid sarcoma begin soft tissue skin extremity though start areas surgical removal considered main treatment cancer localized one area chemotherapy radiation may also however high likelihood local regional spread disease even treatment approximately patients metastatic disease time metastatic disease considered lifethreatening according nci drug dictionary tazemetostat orally available small molecule selective sadenosyl methionine sam competitive inhibitor histone methyl transferase potential antineoplastic activity upon oral administration tazemetostat selectively inhibits activity wildtype mutated forms inhibition specifically prevents methylation histone lysine decrease histone methylation alters gene expression patterns associated cancer pathways results decreased tumor cell proliferation mutated cancer cells belongs class histone methyltransferases hmts overexpressed mutated variety cancer cells plays key role tumor cell us food drug administration fda considers firstinclass us food drug administration fda approved tazemetostat january based results clinical trial enrolling subjects metastatic locally advanced epithelioid clinical trial subjects received milligrams mg tazemetostat twice day disease progressed subject reached unacceptable level tumor response assessments performed every eight weeks clinical trial measured many subjects experienced complete partial shrinkage certain amount tumors treatment overall response overall response rate subjects complete response partial nine subjects response six subjects response lasting six months trial conducted sites france united kingdom taiwan italy canada belgium united fda granted application tazemetostat accelerated approval orphan drug fda granted approval tazverik epizyme httpsenwikipediaorgwikitazemetostat